Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand.
作者信息
Wanlapakorn Nasamon, Suntronwong Nungruthai, Kanokudom Sitthichai, Assawakosri Suvichada, Nilyanimit Pornjarim, Yorsaeng Ritthideach, Chansaenroj Jira, Poovorawan Yong
机构信息
Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok, Thailand.
出版信息
Pathog Glob Health. 2022 Oct;116(7):395-397. doi: 10.1080/20477724.2022.2108646. Epub 2022 Aug 3.
Abstract
摘要
相似文献
1
Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand.泰国BNT162b2新冠疫苗作为两剂不同基础免疫方案后的第三剂（加强针）的免疫原性。
Pathog Glob Health. 2022 Oct;116(7):395-397. doi: 10.1080/20477724.2022.2108646. Epub 2022 Aug 3.
2
Comparison of the reactogenicity and immunogenicity between two-dose mRNA COVID-19 vaccine and inactivated COVID-19 vaccine followed by an mRNA vaccine in children aged 5-11 years.两种 mRNA COVID-19 疫苗与灭活 COVID-19 疫苗序贯加强接种在 5-11 岁儿童中的反应原性和免疫原性比较。
J Med Virol. 2023 May;95(5):e28758. doi: 10.1002/jmv.28758.
3
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.秘鲁利马，在使用 BBIBP-CorV 或 BNT162b2 疫苗进行基础免疫程序后，接种第三剂 BNT162b2 疫苗对 COVID-19 的免疫原性和反应原性。
PLoS One. 2022 Oct 17;17(10):e0268419. doi: 10.1371/journal.pone.0268419. eCollection 2022.
4
Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia.在健康成年人中，全剂量与半剂量的 COVID-19 疫苗（ChAdOx1-S 或 BNT162b2）或 CoronaVac 作为加强针接种后的免疫原性和安全性：在印度尼西亚进行的一项随机、观察者设盲、对照试验。
Lancet Infect Dis. 2023 May;23(5):545-555. doi: 10.1016/S1473-3099(22)00800-3. Epub 2023 Jan 11.
5
Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.KD-414 新冠灭活疫苗在成年人中的单剂加强免疫的免疫原性和安全性：日本一项开放标签、单中心、非随机、对照研究。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2193074. doi: 10.1080/21645515.2023.2193074. Epub 2023 Apr 13.
6
Comparison of humoral immune response in heterologous and homologous COVID-19 booster vaccine groups using CoronaVac and mRNA-based BNT162b2 vaccines.使用科兴和国药的新冠疫苗与辉瑞 mRNA 疫苗加强针的异源和同源免疫应答比较。
Rev Soc Bras Med Trop. 2023 Jul 24;56:e00462023. doi: 10.1590/0037-8682-0046-2023. eCollection 2023.
7
Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].不同 COVID-19 疫苗组合在健康个体中的安全性和免疫原性评估：一项随机、设盲、对照的 3 期临床试验 [PRIBIVAC] 的研究方案。
Trials. 2022 Jun 16;23(1):498. doi: 10.1186/s13063-022-06345-2.
8
Association of a Third Dose of BNT162b2 Vaccine With Incidence of SARS-CoV-2 Infection Among Health Care Workers in Israel.以色列卫生保健工作者中，第三剂 BNT162b2 疫苗接种与 SARS-CoV-2 感染发生率的关联。
JAMA. 2022 Jan 25;327(4):341-349. doi: 10.1001/jama.2021.23641.
9
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.针对 COVID-19 mRNA 疫苗 BNT162b2 作为灭活 SARS-CoV-2 病毒疫苗异源加强针的疫苗有效性的证据综合和汇总分析。
Hum Vaccin Immunother. 2023 Dec 31;19(1):2165856. doi: 10.1080/21645515.2023.2165856. Epub 2023 Feb 1.
10
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies.智利科兴疫苗和加强针的血清学研究：抗 SARS-CoV-2 刺突抗体的免疫原性和持久性。
BMC Med. 2022 Jun 9;20(1):216. doi: 10.1186/s12916-022-02406-0.
引用本文的文献
1
Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina.墨西哥和阿根廷六个月随访期间不同加强疫苗组合对 SARS-CoV-2 的有效性。
Front Immunol. 2024 May 14;15:1403784. doi: 10.3389/fimmu.2024.1403784. eCollection 2024.
2
Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens.不同新冠疫苗接种方案的抗S1 IgA反应评估
Vaccines (Basel). 2023 Jun 19;11(6):1117. doi: 10.3390/vaccines11061117.
3
The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5.12种不同三剂次新冠病毒疫苗接种方案后的第四剂mRNA新冠病毒疫苗：对奥密克戎BA.4/BA.5的安全性和免疫原性
Vaccines (Basel). 2023 Mar 1;11(3):570. doi: 10.3390/vaccines11030570.
4
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax) after homologous and heterologous two-dose regimens.第三剂 COVID-19 蛋白亚单位疫苗（Covovax）在同源和异源两剂方案后的安全性和免疫原性。
Int J Infect Dis. 2023 Jan;126:64-72. doi: 10.1016/j.ijid.2022.11.022. Epub 2022 Nov 22.
本文引用的文献
1
Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination.加强型 mRNA 和腺病毒载体疫苗对异源科兴/阿斯利康疫苗接种后对奥密克戎 BA.1 和 BA.2 的免疫应答的影响。
J Med Virol. 2022 Dec;94(12):5713-5722. doi: 10.1002/jmv.28044. Epub 2022 Aug 10.
2
Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine.两剂BBIBP-CorV疫苗后接种一剂病毒载体和mRNA新冠疫苗作为加强针在已接种两剂BBIBP-CorV疫苗的成年初免者中针对Delta和Omicron变异株的免疫原性
Vaccines (Basel). 2022 Jul 3;10(7):1071. doi: 10.3390/vaccines10071071.
3
Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.两剂阿斯利康 AZD1222 疫苗接种后，健康成年人同源和异源 COVID-19 加强疫苗对奥密克戎 BA.1 和 BA.2 变异株的免疫持久性。
Int J Infect Dis. 2022 Sep;122:793-801. doi: 10.1016/j.ijid.2022.07.038. Epub 2022 Jul 19.
4
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.同源和异源加强针对于灭活 SARS-CoV-2 疫苗的有效性：一项大规模前瞻性队列研究。
Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23.
5
Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.异源灭活和腺病毒载体 COVID-19 疫苗的免疫原性：真实世界数据。
Vaccine. 2022 May 20;40(23):3203-3209. doi: 10.1016/j.vaccine.2022.04.043. Epub 2022 Apr 18.
6
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.在接种两剂科兴疫苗的健康成年人中进行异源加强针后对奥密克戎变异株的中和活性。
J Infect Dis. 2022 Oct 17;226(8):1372-1381. doi: 10.1093/infdis/jiac092.
7
Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.mRNA COVID-19 疫苗 3 剂接种与 SARS-CoV-2 奥密克戎和德尔塔变异株引起的有症状感染之间的关联。
JAMA. 2022 Feb 15;327(7):639-651. doi: 10.1001/jama.2022.0470.
8
Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.英格兰 COVID-19 加强疫苗对与 COVID-19 相关症状、住院和死亡的有效性。
Nat Med. 2022 Apr;28(4):831-837. doi: 10.1038/s41591-022-01699-1. Epub 2022 Jan 14.
Zotero 插件